Creative Commons source reading · Neurodegeneration biomarkers and longitudinal studies
Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease.
Atul Kumar; Maryam Shoai; Sebastian Palmqvist; Erik Stomrud; John Hardy; Niklas Mattsson-Carlgren; Oskar Hansson
Originally published in Scientific reports · 2021-10-06
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Cognitive decline in early-stage Alzheimer's disease (AD) may depend on genetic variability. In the Swedish BioFINDER study, we used polygenic scores (PGS) (for AD, intelligence, and educational attainment) to predict longitudinal cognitive change (measured by mini-mental state examination (MMSE) [primary outcome] and other cognitive tests) over a mean of 4.2 years. We included 260 β-amyloid (Aβ) negative cognitively unimpaired (CU) individuals, 121 Aβ-positive CU (preclinical AD), 50 Aβ-negative mild cognitive impairment (MCI) patients, and 127 Aβ-positive MCI patients (prodromal AD). Statistical significance was determined at Bonferroni corrected p value < 0.05. The PGS for intelligence (beta = 0.1, p = 2.9e-02) was protective against decline in MMSE in CU and MCI participants regardless of Aβ status. The polygenic risk score for AD (beta = - 0.12, p = 9.4e-03) was correlated with the rate of change in MMSE and was partially mediated by Aβ-pathology (mediation effect 20%). There was no effect of education PGS on cognitive measures.
Discussion
In this study of genetic contributions to cognitive decline in the earliest stages of AD, we investigated whether a priori defined PRS/PGS for AD, intelligence and educational attainment were associated with cognitive decline in CU and MCI individuals depending upon their Aβ status. Our main findings were that the PRS for AD was related to the rate of cognitive decline and was partly mediated through Aβ-pathology, while an intelligence PGS was protective in CU and MCI participants irrespective of Aβ status.
Limitations
Although the BioFINDER cohort has extensive phenotyping for cognition and Aβ that is necessary for a study of early-stage AD, the sample size was relatively small. We, therefore, restricted the analysis to genes with MAF ≥ 0.05. More extensive studies would be necessary to consider the rarer genetic variants, which could also be essential for cognitive decline. A higher frequency of testing and longer follow up data must be collected to validate further and optimize these genetic risk predictors. Another limitation is that several brain changes may contribute to cognitive decline in the elderly.
Conclusions
The study evaluated the rate of cognitive decline based on PRS of AD and PGS of intelligence and education. PRS-Alz was associated with rate of cognitive decline and was partly mediated by Aβ, while PGS-Int was protective irrespective of Aβ status. There was no effect of PGS-Edu in any of the populations. Novel genetic associations with the rate of cognitive decline in AD may provide new insights into the pathophysiology of AD and suggest new therapeutic development targets.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
